|
1
|
Lin B, Ma H, Ma M, Zhang Z, Sun Z, Hsieh
IY, Okenwa O, Guan H, Li J and Lv W: The incidence and survival
analysis for anaplastic thyroid cancer: A SEER database analysis.
Am J Transl Res. 11:5888–5896. 2019.PubMed/NCBI
|
|
2
|
Xia Q, Wang W, Xu J, Chen X, Zhong Z and
Sun C: Evidence from an updated meta-analysis of the prognostic
impacts of postoperative radiotherapy and chemotherapy in patients
with anaplastic thyroid carcinoma. Onco Targets Ther. 11:2251–2257.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bible KC, Kebebew E, Brierley J, Brito JP,
Cabanillas ME, Clark TJ Jr, Di Cristofano A, Foote R, Giordano T,
Kasperbauer J, et al: 2021 American thyroid association guidelines
for management of patients with anaplastic thyroid cancer. Thyroid.
31:337–386. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iwasaki H, Yamazaki H, Takasaki H,
Suganuma N, Nakayama H, Toda S and Masudo K: Lenvatinib as a novel
treatment for anaplastic thyroid cancer: A retrospective study.
Oncol Lett. 16:7271–7277. 2018.PubMed/NCBI
|
|
5
|
Iwasaki H, Toda S, Suganuma N, Murayama D,
Nakayama H and Masudo K: Lenvatinib vs palliative therapy for stage
IVC anaplastic thyroid cancer. Mol Clin Oncol. 12:138–143.
2020.PubMed/NCBI
|
|
6
|
Wirth LJ, Brose MS, Sherman EJ, Licitra L,
Schlumberger M, Sherman SI, Bible KC, Robinson B, Rodien P, Godbert
Y, et al: Open-label, single-arm, multicenter, phase II trial of
lenvatinib for the treatment of patients with anaplastic thyroid
cancer. J Clin Oncol. 39:2359–2366. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Higashiyama T, Sugino K, Hara H, Ito KI,
Nakashima N, Onoda N, Tori M, Katoh H, Kiyota N, Ota I, et al:
Phase II study of the efficacy and safety of lenvatinib for
anaplastic thyroid cancer (HOPE). Eur J Cancer. 173:210–218. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dierks C, Seufert J, Aumann K, Ruf J,
Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, et
al: Combination of lenvatinib and pembrolizumab is an effective
treatment option for anaplastic and poorly differentiated thyroid
carcinoma. Thyroid. 31:1076–1085. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim M, Ahn J, Song DE, Yoon JH, Kang HC,
Lim DJ, Kim WG, Kim TY, Kim WB, Shong YK, et al: Real-world
experience of lenvatinib in patients with advanced anaplastic
thyroid cancer. Endocrine. 71:427–433. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Onoda N, Sugino K, Higashiyama T, Kammori
M, Toda K, Ito K, Yoshida A, Suganuma N, Nakashima N, Suzuki S, et
al: The safety and efficacy of weekly paclitaxel administration for
anaplastic thyroid cancer patients: A nationwide prospective study.
Thyroid. 26:1293–1299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wirth LJ, Durante C, Topliss DJ, Winquist
E, Robenshtok E, Iwasaki H, Luster M, Elisei R, Leboulleux S and
Tahara M: Lenvatinib for the treatment of radioiodine-refractory
differentiated thyroid cancer: Treatment optimization for maximum
clinical benefit. Oncologist. 27:565–572. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bogaerts J, Ford R, Sargent D, Schwartz
LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J and Therasse
P; RECIST Working Party, : Individual patient data analysis to
assess modifications to the RECIST criteria. Eur J Cancer.
45:248–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tahara M, Kiyota N, Yamazaki T, Chayahara
N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, et
al: Lenvatinib for anaplastic thyroid cancer. Front Oncol.
7:252017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rendl G, Sipos B, Becherer A, Sorko S,
Trummer C, Raderer M, Hitzl W, Ardelt M, Gallowitsch HJ and Pirich
C: Real-world data for lenvatinib in radioiodine-refractory
differentiated thyroid cancer (relevant): A retrospective
multicentric analysis of clinical practice in Austria. Int J
Endocrinol. 2020:88341482020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu B, Fuchs T, Dogan S, Landa I, Katabi N,
Fagin JA, Tuttle RM, Sherman E, Gill AJ and Ghossein R: Dissecting
anaplastic thyroid carcinoma: A comprehensive clinical, histologic,
immunophenotypic, and molecular study of 360 cases. Thyroid.
30:1505–1517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pozdeyev N, Gay LM, Sokol ES, Hartmaier R,
Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, et
al: Genetic analysis of 779 advanced differentiated and anaplastic
thyroid cancers. Clin Cancer Res. 24:3059–3068. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Subbiah V, Kreitman RJ, Wainberg ZA, Cho
JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME,
Urbanowitz G, et al: Dabrafenib and trametinib treatment in
patients with locally advanced or metastatic BRAF V600-mutant
anaplastic thyroid cancer. J Clin Oncol. 36:7–13. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chintakuntlawar AV, Yin J, Foote RL,
Kasperbauer JL, Rivera M, Asmus E, Garces NI, Janus JR, Liu M, Ma
DJ, et al: A phase 2 study of pembrolizumab combined with
chemoradiotherapy as initial treatment for anaplastic thyroid
cancer. Thyroid. 29:1615–1622. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Subbiah V, Kreitman RJ, Wainberg ZA, Cho
JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME,
Boran A, et al: Dabrafenib plus trametinib in patients with BRAF
V600E-mutant anaplastic thyroid cancer: Updated analysis from the
phase II ROAR basket study. Ann Oncol. 33:406–415. 2022. View Article : Google Scholar : PubMed/NCBI
|
